Bon Secours Mercy Health is reported to be close to buying a controlling stake in Surgery Partners, valuing the Bain Capital-backed surgical operator at about $6 billion including debt. The Financial Times reported the talks on 25 October 2026, and no deal had been officially announced when this was written.
The story matters because a non-profit hospital system would be taking control of a listed, debt-heavy company that runs outpatient surgery centers. Here is what is reported, what is not, and what to watch.
Key takeaways
- The Financial Times reported on 25 October 2026 that Bon Secours is nearing a deal for a controlling stake in Surgery Partners (Nasdaq: SGRY).
- The $6 billion figure is an enterprise value, meaning equity plus debt, not the price of the stake alone.
- Reports cite roughly $20 a share, about a 25% premium to a recent price near $16, and about $3.5 billion of debt.
- Bain Capital is reported to stay on with close to 40%.
- Nothing is signed. Terms can still change.
What is the Bon Secours Surgery Partners deal?
According to the FT, as relayed by GuruFocus and Briefs, Bon Secours Mercy Health is in late-stage talks to buy a majority interest in Surgery Partners. Bloomberg also carried the report, and Reuters picked it up.
The reports describe an announcement as possible as early as 26 October 2026. They give no exact percentage for the stake. The sales process is said to have run for more than a year.
Who are the two companies?
Surgery Partners, based in Brentwood, Tennessee, runs ambulatory surgery centers (outpatient facilities where patients have planned procedures and go home the same day) and surgical hospitals. Reports put it at 176 facilities across 30 US states.
Bon Secours Mercy Health is a Catholic non-profit health system. Reports put it at 47 hospitals and about $14 billion of revenue last year.
| Item | Reported detail |
|---|---|
| Buyer | Bon Secours Mercy Health |
| Target | Surgery Partners (SGRY) |
| Enterprise value | About $6 billion, including debt |
| Debt | About $3.5 billion |
| Price per share | About $20 |
| Bain Capital | Stays on with close to 40% |
| Status | Talks close to final, unsigned |
Why does the $6 billion number need care?
Enterprise value is what a business is worth to all its funders. Think of buying a house with a mortgage: the house is worth the full price, but your cash is only the down payment.
With about $3.5 billion of debt in that figure, the equity is worth roughly $2.5 billion. A buyer taking a controlling stake would pay for only part of that.
What did Bain Capital do before?
Bain already held about 39% of the company. In January 2025 it proposed buying out the rest at $25.75 a share, valuing the company at about $3.3 billion in equity, according to Becker’s ASC Review. Surgery Partners later ended those talks.
Reports also say Bain walked away from a separate deal that valued the company at $6.7 billion enterprise value. Earlier suitors in 2024 reportedly included TPG and UnitedHealth Group. So this is a long sale process, not a sudden one.
How has the stock behaved?
Surgery Partners shares closed at $15.32 on 4 August 2026, according to a Benzinga snapshot. Coverage of the deal cites a recent price near $16. A $20 offer would sit roughly 25% above that.
The company reported first-quarter 2026 revenue of $810.9 million and a net loss of $35.9 million. It kept full-year revenue guidance at $3.35 billion to $3.45 billion. Debt is the usual worry with this company.
Why would a non-profit health system want this?
The reports do not give Bon Secours’ reasoning, so this part is my opinion. Outpatient surgery has grown as procedures move out of hospitals, and owning centers gives a hospital system more control over where those procedures happen.
Bon Secours already works in this area. It has expanded a partnership with Compass Surgical Partners to develop more than 30 surgery centers. Buying a platform would be a much bigger step than building them one by one.
What happens next
- An announcement or a collapse. Reports say a deal could come as early as 26 October 2026. Talks of this kind can still fall apart.
- The final terms. Watch the exact stake size, the price per share and how the $3.5 billion of debt is handled.
- Approvals. A deal of this size would likely need shareholder and regulatory sign-off. That is my expectation, not something the reports state.
- Bain’s exit. The reports say it stays on near 40%, so a full exit is not part of this deal.
FAQ
Is the Bon Secours Surgery Partners deal confirmed?
No. It rests on Financial Times reporting from 25 October 2026 that describes talks as close to final. Neither company had announced a signed agreement.
Is $6 billion what Bon Secours would pay?
Not exactly. It is the reported enterprise value, which includes about $3.5 billion of debt. The cost of a controlling stake would be only part of it.
What happens to Bain Capital?
Reports say Bain would stay as a major shareholder with close to 40%.
Want to follow this one? Check the companies’ own press releases for the final terms, and read the filings before trusting any headline number.
This article is for information only and is not investment advice.
Leave a comment